Market Analysis and Insights:- Global Deep vein thrombosis (DVT) Treatment Market
Global Deep vein thrombosis (DVT) Treatment Market By Treatment Type (Medication, Devices and Surgery), Drugs (Anticoagulants, Heparin, Others), Devices (Neurovascular Embolectomy Devices, Inferior VenaCava Filters (IVCF) and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026
Market Analysis: Global Deep Vein Thrombosis (DVT) Treatment Market
Global Deep vein thrombosis (DVT) treatment market is growing at a growing CAGR of 8.5% in the forecast period of 2019-2026. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth
Market Definition: Global Deep Vein Thrombosis (DVT) Treatment Market
Deep Vein Thrombosis (DVT) is the formation of blood clots (also known as thrombosis) in a deep vein in the body. DVT is predominantly occurs in the legs but can occur in the pelvic aareas and arms. It can lead to partial or completed blockage of circulation which eventually causes some serious medical problems.
According to the statistics published in the Indiana Vein Specialists, an estimated annual prevalence of deep vein thrombosis is up to 2 million in the United States. Growing cases of cardiovascular disorders and increases prevalence of this condition are the key factors for growth of the market.
Get More Insight About the Global Deep vein thrombosis (DVT) Treatment Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-deep-vein-thrombosis-dvt-treatment-market
Market Drivers
- Increase prevalence of Deep Vein Thrombosis (DVT) worldwide is drive the growth of the market
- Growing burden of cardiovascular and trauma cases is act as drivers for market growth
- Rising improvement in health insurance coverage and availability of emergency medical services is accelerating the market growth
- Huge financial support to the researchers for developing novel intervention is enhancing the market growth
Market Restraints
- The inaccessibility and unaffordability of the effective treatment is hampering the market growth
- Lack of trained personnel and stringent safety regulations is hampering the market growth
- Rise in cases of product recalls are expect to cause a shortfall in the market
Know More About this Report @ https://www.databridgemarketresearch.com/reports/global-deep-vein-thrombosis-dvt-treatment-market
Segmentation: Global Deep Vein Thrombosis (DVT) Treatment Market
By Treatment Type
- Medication
- Devices
- Surgery
By Drugs
- Anticoagulants
- Rivaroxaban
- Apixaban
- Others
- Heparin
- Heparin sodium
- Dalteparin sodium
- Others
- Others
By Devices
- Neurovascular Embolectomy Devices
- Inferior VenaCava Filters (IVCF)
- Others
By Route of Administration
- Oral
- Injectable
By End Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
By Geography
- North America
- U.S.
- Canada
- Mexico
- South America
- Brazil
- Rest of South America
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Turkey
- Belgium
- Netherlands
- Switzerland
- Rest of Europe
- Asia-Pacific
- Japan
- China
- South Korea
- India
- Australia
- Singapore
- Thailand
- Malaysia
- Indonesia
- Philippines
- Rest of Asia Pacific
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Key Developments in the Market:
In Jan 2018, Baxter received the FDA approval for Bivalirudin, direct thrombin inhibitor for the treatment of patients undergoing percutaneous coronary intervention and deep vein thrombosis. A introduction of convenient frozen premixed solution of bivalirudin promote efficiency treatment for patients with this devastated condition.
In November 2017, DAIICHI SANKYO COMPANY, LIMITED launched Lixiana (doxaban tosilate hydrate), an oral anticoagulants for the treatment of recurrence prevention of venous thromboembolism, deep vein thrombosis and pulmonary thromboembolism in the Japan. The launch of Lixiana will significantly change treatment landscape for patients with deep vein thrombosis throughout the Japan.
Competitive Analysis:
Global deep vein thrombosis (DVT) treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global deep vein thrombosis (DVT) treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Players:
Few of the major competitors currently working in the global deep vein thrombosis (DVT) treatment market are Aspen Holdings, Novartis AG, Mylan N.V., Momenta Pharmaceuticals, Inc, Hikma Pharmaceuticals PLC, Laboratorios Farmaceuticos Rovi, S.A., GL Pharma, Cobapharma, Boehringer Ingelheim GmbH, Glenmark Pharmaceuticals Inc., Bristol-Myers Squibb Company, Portola Pharmaceuticals, Inc. Daiichi Sankyo Company, Limited, Johnson & Johnson Services, Inc., Bayer AG, Bausch Health, Vasudha Pharma, Tianyu Pharmaceutical Co., Ltd., Neuland Laboratories Ltd, Mitsubishi Tanabe Pharma Corporation and others.
Research Methodology: Global Deep Vein Thrombosis (DVT) Treatment Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-deep-vein-thrombosis-dvt-treatment-market
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Primary Respondents
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Reasons to Purchase this Report
- Current and future of global deep vein thrombosis (DVT) treatment market outlook in the developed and emerging markets
- The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
- Regions/Countries that are expected to witness the fastest growth rates during the forecast period
- The latest developments, market shares, and strategies that are employed by the major market players
Access Full report @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-deep-vein-thrombosis-dvt-treatment-market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
Market Analysis and Insights:- Global Deep vein thrombosis (DVT) Treatment MarketGlobal Deep vein thrombosis (DVT) Treatment Market By Treatment Type (Medication, Devices and Surgery), Drugs (Anticoagulants, Heparin, Others), Devices (Neurovascular Embolectomy Devices, Inferior VenaCava Filters (IVCF) and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026Market Analysis: Global Deep Vein Thrombosis (DVT) Treatment MarketGlobal Deep vein thrombosis (DVT) treatment market is growing at a growing CAGR of 8.5% in the forecast period of 2019-2026.
Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growthMarket Definition: Global Deep Vein Thrombosis (DVT) Treatment MarketDeep Vein Thrombosis (DVT) is the formation of blood clots (also known as thrombosis) in a deep vein in the body.
It can lead to partial or completed blockage of circulation which eventually causes some serious medical problems.According to the statistics published in the Indiana Vein Specialists, an estimated annual prevalence of deep vein thrombosis is up to 2 million in the United States.
Growing cases of cardiovascular disorders and increases prevalence of this condition are the key factors for growth of the market.Get More Insight About the Global Deep vein thrombosis (DVT) Treatment Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-deep-vein-thrombosis-dvt-treatment-market Market DriversIncrease prevalence of Deep Vein Thrombosis (DVT) worldwide is drive the growth of the marketGrowing burden of cardiovascular and trauma cases is act as drivers for market growthRising improvement in health insurance coverage and availability of emergency medical services is accelerating the market growthHuge financial support to the researchers for developing novel intervention is enhancing the market growth Market RestraintsThe inaccessibility and unaffordability of the effective treatment is hampering the market growthLack of trained personnel and stringent safety regulations is hampering the market growthRise in cases of product recalls are expect to cause a shortfall in the marketKnow More About this Report @ https://www.databridgemarketresearch.com/reports/global-deep-vein-thrombosis-dvt-treatment-marketSegmentation: Global Deep Vein Thrombosis (DVT) Treatment MarketBy Treatment TypeMedicationDevicesSurgeryBy DrugsAnticoagulantsRivaroxabanApixabanOthersHeparinHeparin sodiumDalteparin sodiumOthersOthersBy Devices Neurovascular Embolectomy DevicesInferior VenaCava Filters (IVCF)OthersBy Route of AdministrationOralInjectableBy End UsersHospitalsHomecareSpecialty ClinicsOthersBy GeographyNorth AmericaU.S.CanadaMexicoSouth AmericaBrazilRest of South AmericaEuropeGermanyFranceUnited KingdomItalySpainRussiaTurkeyBelgiumNetherlandsSwitzerlandRest of EuropeAsia-PacificJapanChinaSouth KoreaIndiaAustraliaSingaporeThailandMalaysiaIndonesiaPhilippinesRest of Asia PacificMiddle East & AfricaSouth AfricaRest of Middle East & AfricaKey Developments in the Market: In Jan 2018, Baxter received the FDA approval for Bivalirudin, direct thrombin inhibitor for the treatment of patients undergoing percutaneous coronary intervention and deep vein thrombosis.
A introduction of convenient frozen premixed solution of bivalirudin promote efficiency treatment for patients with this devastated condition.In November 2017, DAIICHI SANKYO COMPANY, LIMITED launched Lixiana (doxaban tosilate hydrate), an oral anticoagulants for the treatment of recurrence prevention of venous thromboembolism, deep vein thrombosis and pulmonary thromboembolism in the Japan.
The report includes market shares of global deep vein thrombosis (DVT) treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.Key Market Players:Few of the major competitors currently working in the global deep vein thrombosis (DVT) treatment market are Aspen Holdings, Novartis AG, Mylan N.V., Momenta Pharmaceuticals, Inc, Hikma Pharmaceuticals PLC, Laboratorios Farmaceuticos Rovi, S.A., GL Pharma, Cobapharma, Boehringer Ingelheim GmbH, Glenmark Pharmaceuticals Inc., Bristol-Myers Squibb Company, Portola Pharmaceuticals, Inc. Daiichi Sankyo Company, Limited, Johnson & Johnson Services, Inc., Bayer AG, Bausch Health, Vasudha Pharma, Tianyu Pharmaceutical Co., Ltd., Neuland Laboratories Ltd, Mitsubishi Tanabe Pharma Corporation and others.Research Methodology: Global Deep Vein Thrombosis (DVT) Treatment MarketData collection and base year analysis is done using data collection modules with large sample sizes.
The Global Venous thromboembolism (VTE) Therapeutics Market is projected to grow at a healthy growth rate from 2018 to 2025 according to new research.
The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies.
It also presents insights into various restraints that pose threat and highlights opportunities that will help the market pick pace in the forthcoming years.
The report compiles exhaustive information obtained via proven research methodologies and from trusted sources from within the industries.
It also includes expert opinions to provide readers a clearer perspective regarding the global market.
The report segments the global Venous thromboembolism (VTE) Therapeutics market as: Global Venous thromboembolism (VTE) Therapeutics Market: Regional Segment AnalysisNorth AmericaEuropeChinaJapanIndiaSoutheast AsiaOther regions (Central & South America, Middle East & Africa) Global Venous thromboembolism (VTE) Therapeutics Market: Type Segment AnalysisDeep Vein Thrombosis(DVT)Pulmonary Embolism(PE) Global Venous thromboembolism (VTE) Therapeutics Market: Application Segment AnalysisHospitalASCsResearch Institutes Global Venous thromboembolism (VTE) Therapeutics Market: Manufacturers Segment AnalysisBoehringer IngelheimBayerJanssenBristol-Myers SquibbPfizerDaiichi-SankyoPortola PharmaceuticalsArmetheon Global Venous thromboembolism (VTE) Therapeutics Market: Key StakeholdersVenous thromboembolism (VTE) Therapeutics ManufacturersVenous thromboembolism (VTE) Therapeutics Distributors/Traders/WholesalersVenous thromboembolism (VTE) Therapeutics Subcomponent ManufacturersIndustry AssociationDownstream Vendors For More Information Click Here @ https://www.upmarketresearch.com/home/enquiry_before_buying/6940 In this study, the years considered to estimate the market size of Venous thromboembolism (VTE) Therapeutics are as follows:History Year: 2013-2017Base Year: 2017Estimated Year: 2018Forecast Year 2018 to 2025 The micro and macroeconomic factors influencing the growth of the market are covered in the detailed study of the Venous thromboembolism (VTE) Therapeutics Market analysis report published on Up Market Research.
The growth in the anticoagulation drugs market is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs).Major Growth Drivers:Market growth is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs).Expected Revenue Growth:[86 Pages Report] The US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022 from USD 17.25 Billion in 2016, at a CAGR of 8.5%.Accessories to Fuel the Growth of US Anticoagulation Therapy Market :In this report, the US anticoagulation therapy market is segmented on the basis of products and clinics.
On the basis of products, the market is segmented into anticoagulation drugs and PT/INR testing devices.Browse in-depth TOC on “US Anticoagulation Therapy Market”29 – Tables25 – Figures86 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=114158575Based on drug type, the anticoagulation therapy market for drugs is segmented into NOACs, warfarin (VKA), and other drugs.
In 2016, the NOACs segment dominated the US anticoagulation therapy market for drugs.
In addition, key market players such as Portola Pharmaceuticals (received FDA approval for its NOAC Betrixaban in July 2017) are focusing on the development of NOACs in order to capitalize on the growth opportunities presented by this shift in market dynamicsThe anticoagulation therapy market for PT/INR testing devices is segmented into in-office testing devices and home testing devices.
The large share of this segment is mainly attributed to the large number of patients opting for in-office testing services.The anticoagulation therapy market for clinics is segmented on the basis of type of services and clinics.
The types of clinics include hospital associated clinics, independent clinics, and pharmacy-based clinics while the types of services include testing services and consulting services.
High cost of NOACs and requirement of significant investments in the development of anticoagulation drugs are the major factors restraining the growth of this market.
In addition, the growth in the anticoagulation clinics market is primarily driven by the increasing prevalence of cardiovascular diseases & blood disorders, high level of medication adherence associated with clinics, and rising aging population.Major Growth Drivers:The market is segmented into products (anticoagulation drugs and PT/INR testing devices) and anticoagulation clinics.
Major players in the market were identified through secondary sources; directories; databases such as Hoovers, Bloomberg Businessweek, Factiva, and OneSource, journals and their market revenues were determined through primary and secondary research.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=114158575Based on drug type, the anticoagulation therapy market for drugs is segmented into NOACs, warfarin (VKA), and other drugs.
Due to the better safety and efficacy of NOACs as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs.The anticoagulation therapy market for PT/INR testing devices is segmented into in-office testing devices and home testing devices.
The large share of this segment is mainly attributed to the large number of patients opting for in-office testing services.The anticoagulation therapy market for clinics is segmented on the basis of type of services and clinics.
The types of clinics include hospital associated clinics, independent clinics, and pharmacy-based clinics while the types of services include testing services and consulting services.
Venous Thromboembolism Treatment Market report published by Value Market Research, which studies the future outlook of the market.
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the venous thromboembolism treatment market include Argon Medical Devices, Arjo, Boston Scientific, Cardinal Health (Medtronic), Cook Medical, DJO Global, Koninklijke Philips N.V., and Stryker.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Venous Thromboembolism Treatment Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/venous-thromboembolism-treatment-market/download-sampleMarket DynamicsThe key drivers behind global venous thromboembolism treatment market growth are increasing incidence of VTE and increasing awareness about the existing treatment options.
Introduction of new VTE treatment devices, increasing the number of treatment choices for patients will contribute significantly towards VTE treatment market.
Furthermore, technological advancements in VTE treatment, such as, development of heparins and associated inhibitors with low molecular weight are expected to bring lucrative growth opportunities for VTE market.
